APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Zoster Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Recombinant Zoster Vaccine Market Outlook and Growth Opportunities 2026

Report ID 174031920430 December 2025196 pages

Choose your research edition.

Industry ResearchRecombinant Zoster Vaccine Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Zoster Vaccine Industry Growth and Trends Forecast to 203270 pages · $3,450 USDMarket StructureGlobal Recombinant Zoster Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Zoster Vaccine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Zoster Vaccine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Recombinant Zoster Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Recombinant Zoster Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Zoster Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Zoster Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Recombinant Zoster Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Recombinant Zoster Vaccine market include GSK, Merck and Changchun Bcht Biotechnology, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant Zoster Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Zoster Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Zoster Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Zoster Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Zoster Vaccine Segment by Company

GSK

Merck

Changchun Bcht Biotechnology

Recombinant Zoster Vaccine Segment by Type

Monovalent Vaccine

Combination Vaccine

Recombinant Zoster Vaccine Segment by Application

Above 50 Years Old

Below 50 Years Old

Recombinant Zoster Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Recombinant Zoster Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Recombinant Zoster Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Recombinant Zoster Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Recombinant Zoster Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Zoster Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Zoster Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Zoster Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Zoster Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant Zoster Vaccine industry.

Chapter 3: Detailed analysis of Recombinant Zoster Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Recombinant Zoster Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Recombinant Zoster Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Recombinant Zoster Vaccine Industry Trends Table 2. Recombinant Zoster Vaccine Industry Drivers Table 3. Recombinant Zoster Vaccine Industry Opportunities and Challenges Table 4. Recombinant Zoster Vaccine Industry Restraints Table 5. Global Recombinant Zoster Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Recombinant Zoster Vaccine Revenue Share by Company (2021-2026) Table 7. Global Recombinant Zoster Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Recombinant Zoster Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Recombinant Zoster Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Recombinant Zoster Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Recombinant Zoster Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Recombinant Zoster Vaccine Company, Product Type & Application Table 13. Global Recombinant Zoster Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant Zoster Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Monovalent Vaccine Table 18. Significant Companies of Combination Vaccine Table 19. Global Recombinant Zoster Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Recombinant Zoster Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Recombinant Zoster Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Recombinant Zoster Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Recombinant Zoster Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Recombinant Zoster Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Recombinant Zoster Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Recombinant Zoster Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Recombinant Zoster Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Recombinant Zoster Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Above 50 Years Old Table 30. Significant Companies of Below 50 Years Old Table 31. Global Recombinant Zoster Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Recombinant Zoster Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Recombinant Zoster Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Recombinant Zoster Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Recombinant Zoster Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Recombinant Zoster Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Recombinant Zoster Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Recombinant Zoster Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Recombinant Zoster Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Recombinant Zoster Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Recombinant Zoster Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Recombinant Zoster Vaccine Sales by Region (2021-2026) & (K Units) Table 43. Global Recombinant Zoster Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Recombinant Zoster Vaccine Sales by Region (2027-2032) & (K Units) Table 45. Global Recombinant Zoster Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Recombinant Zoster Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Recombinant Zoster Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Recombinant Zoster Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Recombinant Zoster Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Recombinant Zoster Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Recombinant Zoster Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Recombinant Zoster Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Recombinant Zoster Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Recombinant Zoster Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Recombinant Zoster Vaccine Sales by Country (2021-2026) & (K Units) Table 56. Global Recombinant Zoster Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Recombinant Zoster Vaccine Sales by Country (2027-2032) & (K Units) Table 58. Global Recombinant Zoster Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Recombinant Zoster Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Recombinant Zoster Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Recombinant Zoster Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Recombinant Zoster Vaccine Sales Value Market Share by Country (2027-2032) Table 63. GSK Company Information Table 64. GSK Business Overview Table 65. GSK Recombinant Zoster Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. GSK Recombinant Zoster Vaccine Product Portfolio Table 67. GSK Recent Development Table 68. Merck Company Information Table 69. Merck Business Overview Table 70. Merck Recombinant Zoster Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Merck Recombinant Zoster Vaccine Product Portfolio Table 72. Merck Recent Development Table 73. Changchun Bcht Biotechnology Company Information Table 74. Changchun Bcht Biotechnology Business Overview Table 75. Changchun Bcht Biotechnology Recombinant Zoster Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Changchun Bcht Biotechnology Recombinant Zoster Vaccine Product Portfolio Table 77. Changchun Bcht Biotechnology Recent Development Table 78. Key Raw Materials Table 79. Raw Materials Key Suppliers Table 80. Recombinant Zoster Vaccine Distributors List Table 81. Recombinant Zoster Vaccine Customers List Table 82. Research Programs/Design for This Report Table 83. Authors List of This Report Table 84. Secondary Sources Table 85. Primary Sources List of Figures Figure 1. Recombinant Zoster Vaccine Product Image Figure 2. Global Recombinant Zoster Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Zoster Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Recombinant Zoster Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Recombinant Zoster Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Recombinant Zoster Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Monovalent Vaccine Image Figure 10. Combination Vaccine Image Figure 11. Global Recombinant Zoster Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Recombinant Zoster Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Recombinant Zoster Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Recombinant Zoster Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Recombinant Zoster Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Recombinant Zoster Vaccine Sales Value Share by Type (2021-2032) Figure 17. Above 50 Years Old Image Figure 18. Below 50 Years Old Image Figure 19. Global Recombinant Zoster Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Recombinant Zoster Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Recombinant Zoster Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Recombinant Zoster Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Recombinant Zoster Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Recombinant Zoster Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Recombinant Zoster Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Recombinant Zoster Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Recombinant Zoster Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Recombinant Zoster Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Recombinant Zoster Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Recombinant Zoster Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Recombinant Zoster Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Recombinant Zoster Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Recombinant Zoster Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Recombinant Zoster Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Recombinant Zoster Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Recombinant Zoster Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Recombinant Zoster Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Recombinant Zoster Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Recombinant Zoster Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Recombinant Zoster Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Monovalent Vaccine
  • Combination Vaccine
Applications
  • Above 50 Years Old
  • Below 50 Years Old
Companies covered
  • GSK
  • Merck
  • Changchun Bcht Biotechnology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Recombinant Zoster Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Recombinant Zoster Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Recombinant Zoster Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Recombinant Zoster Vaccine Market Dynamics
  1. 2.1 Recombinant Zoster Vaccine Industry Trends
  2. 2.2 Recombinant Zoster Vaccine Industry Drivers
  3. 2.3 Recombinant Zoster Vaccine Industry Opportunities and Challenges
  4. 2.4 Recombinant Zoster Vaccine Industry Restraints
3 Recombinant Zoster Vaccine Market by Company
  1. 3.1 Global Recombinant Zoster Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Recombinant Zoster Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Recombinant Zoster Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Recombinant Zoster Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Recombinant Zoster Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Recombinant Zoster Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Recombinant Zoster Vaccine Company Product Type and Application
  8. 3.8 Global Recombinant Zoster Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Recombinant Zoster Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Recombinant Zoster Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Recombinant Zoster Vaccine Market by Type
  1. 4.1 Recombinant Zoster Vaccine Type Introduction
  2. 4.1.1 Monovalent Vaccine
  3. 4.1.2 Combination Vaccine
  4. 4.2 Global Recombinant Zoster Vaccine Sales Volume by Type
  5. 4.2.1 Global Recombinant Zoster Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Recombinant Zoster Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Recombinant Zoster Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Recombinant Zoster Vaccine Sales Value by Type
  9. 4.3.1 Global Recombinant Zoster Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Recombinant Zoster Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Recombinant Zoster Vaccine Sales Value Share by Type (2021-2032)
5 Recombinant Zoster Vaccine Market by Application
  1. 5.1 Recombinant Zoster Vaccine Application Introduction
  2. 5.1.1 Above 50 Years Old
  3. 5.1.2 Below 50 Years Old
  4. 5.2 Global Recombinant Zoster Vaccine Sales Volume by Application
  5. 5.2.1 Global Recombinant Zoster Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Recombinant Zoster Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Recombinant Zoster Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Recombinant Zoster Vaccine Sales Value by Application
  9. 5.3.1 Global Recombinant Zoster Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Recombinant Zoster Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Recombinant Zoster Vaccine Sales Value Share by Application (2021-2032)
6 Recombinant Zoster Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Recombinant Zoster Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Zoster Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant Zoster Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Recombinant Zoster Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Recombinant Zoster Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Recombinant Zoster Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Recombinant Zoster Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Recombinant Zoster Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Recombinant Zoster Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Recombinant Zoster Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Recombinant Zoster Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Recombinant Zoster Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Recombinant Zoster Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Recombinant Zoster Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Recombinant Zoster Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Recombinant Zoster Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Recombinant Zoster Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Recombinant Zoster Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Recombinant Zoster Vaccine Sales Value Share by Country, 2025 VS 2032
7 Recombinant Zoster Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Recombinant Zoster Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Recombinant Zoster Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Recombinant Zoster Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Recombinant Zoster Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Recombinant Zoster Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Recombinant Zoster Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Recombinant Zoster Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Recombinant Zoster Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Recombinant Zoster Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Recombinant Zoster Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Recombinant Zoster Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Recombinant Zoster Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Recombinant Zoster Vaccine Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Recombinant Zoster Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Recombinant Zoster Vaccine Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Changchun Bcht Biotechnology
  14. 8.3.1 Changchun Bcht Biotechnology Company Information
  15. 8.3.2 Changchun Bcht Biotechnology Business Overview
  16. 8.3.3 Changchun Bcht Biotechnology Recombinant Zoster Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Changchun Bcht Biotechnology Recombinant Zoster Vaccine Product Portfolio
  18. 8.3.5 Changchun Bcht Biotechnology Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant Zoster Vaccine Value Chain Analysis
  2. 9.1.1 Recombinant Zoster Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant Zoster Vaccine Sales Mode & Process
  6. 9.2 Recombinant Zoster Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant Zoster Vaccine Distributors
  9. 9.2.3 Recombinant Zoster Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst